Anavex Life Sciences Corp

Anavex Life Sciences Corp. a clinical stage biopharmaceutical company engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73 which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy infantile spasms Fragile X syndrome Angelman syndrome multiple sclerosis and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71 which is in Phase I clinical trial for the treatment of frontotemporal dementia; and preclinical clinical trials for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41 a sigma-1 receptor agonist for the treatment of depression stroke Parkinson's and Alzheimer's diseases; ANAVEX 1066 a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York New York.